| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,210 | 0,230 | 13:05 | |
| 0,206 | 0,230 | 06.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | FibroBiologics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| Do | FibroBiologics, Inc.: FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia | 2 | GlobeNewswire (USA) | ||
| 13.01. | After-Hours Biotech Rally: FBLG, NYXH, FBIO, RVTY, OPCH, ATNM, DSGN Climb On Earnings And Momentum | 642 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Several biotech and healthcare names posted notable gains in Monday's after-hours trading session, with moves driven by earnings updates, guidance announcements... ► Artikel lesen | |
| 07.01. | FibroBiologics to begin diabetic foot ulcer clinical trial in Q1 2026 | 5 | Investing.com | ||
| 07.01. | FibroBiologics, Inc.: FibroBiologics CEO Issues Letter to Shareholders | 391 | GlobeNewswire (Europe) | HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| 05.01. | FibroBiologics reports positive results for disc degeneration therapy | 2 | Investing.com | ||
| 02.01. | FibroBiologics droht Delisting von der NASDAQ - Unternehmen beantragt Anhörung | 13 | Investing.com Deutsch | ||
| 02.01. | FibroBiologics, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| FIBROBIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 02.01. | FibroBiologics: H.C. Wainwright bestätigt Kaufempfehlung nach IND-Antrag für Psoriasis-Mittel | 10 | Investing.com Deutsch | ||
| 02.01. | FibroBiologics stock maintains Buy rating at H.C. Wainwright on psoriasis IND filing | 2 | Investing.com | ||
| 31.12.25 | FibroBiologics files IND application for psoriasis treatment | 2 | Investing.com | ||
| 31.12.25 | Psoriasis-Therapie: FibroBiologics reicht IND-Antrag bei FDA ein | 1 | Investing.com Deutsch | ||
| 31.12.25 | Fibrobiologics-Aktie steigt nach FDA-Antrag für Psoriasis-Behandlung | 9 | Investing.com Deutsch | ||
| 31.12.25 | FibroBiologics, Inc.: FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis | 3 | GlobeNewswire (USA) | ||
| 23.12.25 | FibroBiologics, Inc. - S-1, General form for registration of securities | 13 | SEC Filings | ||
| 16.12.25 | FibroBiologics, Inc.: FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 15.12.25 | FibroBiologics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.25 | Hedge Fund and Insider Trading News: AQR Capital Management, Bridgewater Associates, Shiprock Capital Management, Totus Capital, Sage Capital, Global Payments Inc (GPN), FibroBiologics Inc. (FBLG), and More | 6 | Insider Monkey | ||
| 15.12.25 | FibroBiologics raises $1.7 million in registered direct offering | 3 | Investing.com | ||
| 15.12.25 | FibroBiologics sichert sich 1,7 Mio. US-Dollar durch registrierte Direktplatzierung | 4 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| PAION | 0,200 | +8,11 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WIRD GEPRUEFT | Fuer folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wird ein Mistrade-Antrag geprueft:ISIN Datum Zeit Volumen Preis Fair Value (AS)DE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| NANOREPRO | 1,535 | +2,68 % | NanoRepro ordnet Aufsichtsrat nach außerordentlicher HV neu | Die Aktionäre der NanoRepro AG haben auf der außerordentlichen Hauptversammlung vom 16. Januar 2026 den Aufsichtsrat neu zusammengesetzt. Neu gewählt wurden Gunter Heneis, Michael Herrmann und Konstantin... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,365 | -0,27 % | Defence Therapeutics Inc.: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform | Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,392 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | ||
| DYNAVAX | 13,085 | -0,19 % | Laufende Fusionskontrollverfahren: Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USA | Datum der Anmeldung:05.01.2026Aktenzeichen:B3-21/26Unternehmen:Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USAProduktmärkte:monovalenter... ► Artikel lesen | |
| ABIVAX | 98,30 | -0,30 % | ABIVAX Société Anonyme (ABVX): A Bull Case Theory | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen |